Results 301 to 310 of about 3,108,169 (356)

Variation in Immune and Inflammatory Blood Markers in Advanced Melanoma Patients Treated with PD-1 Inhibitors: A Preliminary Exploratory Study. [PDF]

Biomedicines
Bolovan LM, Panait ME, Busca A, Stanciu AE, Chiriac D, Mihalcea CE, Hotnog CM, Georgescu MT, Voinea SC, Prunoiu VM, Brasoveanu LI, Gales LN.   +11 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

Lancet, The, 2014
Caroline Robert, Antoni Ribas, Omid Hamid   +2 more
exaly   +2 more sources

Advanced conjunctival melanoma

Canadian Journal of Ophthalmology, 2004
Conjunctival melanoma is a rare neoplasm with an aggressive behaviour characterized by a high tendency to develop recurrences and metastases. The authors describe the clinicopathological features of four Mexican patients with advanced conjunctival melanoma.Review of the cases of four patients with advanced conjunctival melanoma seen at an ...
Abelardo A, Rodríguez-Reyes, Dolores, Ríos y Valles-Valles, Sonia, Corredor-Casas, Alfredo, Gómez-Leal   +3 more
openaire   +2 more sources

Biochemotherapy for advanced melanoma

Critical Reviews in Oncology/Hematology, 2002
The combination of cisplatin-based chemotherapy with interleukin-2 and interferon-alpha, referred to as biochemotherapy or chemoimmunotherapy, has shown promising antitumor activity in patients with metastatic melanoma. Phase II studies have reported overall response rates ranging from 40 to 60%, with durable complete remissions in approximately 10% of
Ulrich, Keilholz, Martin E, Gore
openaire   +4 more sources

Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma

Journal of Clinical Oncology, 2023
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available.
C. Robert, M. Carlino, C. McNeil, A. Ribas, J. Grob, J. Schachter, M. Nyakas, D. Kee, T. Petrella, A. Blaustein, M. Lotem, A. Arance, A. Daud, O. Hamid, J. Larkin, James Anderson, C. Krepler, Dmitri O. Grebennik, G. Long   +18 more
semanticscholar   +1 more source

THERAPEUTIC ADVANCES IN MELANOMA

Dermatologic Clinics, 2000
Therapy for melanoma continues to evolve, and with the expanding work in the basic pathophysiology, the continued development of biologic modifiers is expected. With new treatment regimens, the rate of remissions is improving for patients with metastatic disease.
J M, Pitts, M E, Maloney
openaire   +2 more sources

Advances in cutaneous melanoma

Clinical and Translational Oncology, 2012
After several decades of slow progress in the field of melanoma, significant advances have been reported in recent years. These include a better understanding of the molecular biology of the tumour, a new staging classification system, insights into the patterns of relapse in early stage, and new drugs for the treatment of advanced disease.
Enrique, Espinosa, Alfonso, Berrocal, José Antonio, López Martín, María, González Cao, Pablo, Cerezuela, José Ignacio, Mayordomo, Salvador, Martín Algarra   +6 more
openaire   +2 more sources

Recent Advances in Melanoma Tumorigenesis

Journal of Drugs in Dermatology, 2022
Melanoma is a tumor that continues to increase in both the number of cases presenting and mortality. Patients with disease that has spread beyond the cutaneous boundary still suffer from significant morbidity and mortality despite advances in immune therapy.
Michael, Bernhardt, Aaron, Bernhardt
openaire   +2 more sources

Activity and safety of first-line treatments for advanced melanoma: A network meta-analysis.

European Journal of Cancer, 2023
BACKGROUND Treatment options for advanced melanoma have increased with the US Food and Drug Administration approval of the anti-LAG3 plus anti-PD-1 relatlimab/nivolumab combination.
A. Boutros, E. Tanda, E. Croce, F. Catalano, M. Ceppi, M. Bruzzone, F. Cecchi, L. Arecco, M. Fraguglia, P. Pronzato, C. Genova, L. Del Mastro, M. Lambertini, F. Spagnolo   +13 more
semanticscholar   +1 more source

Advances in melanoma therapy

Journal of the American Academy of Dermatology, 1998
This review discusses several advances in melanoma therapy that have recently occurred or are presently in a developmental stage. We discuss the history and present dogma regarding assessment of the regional lymph nodes and adjuvant therapy for melanoma.
T M, Johnson, A M, Yahanda, A E, Chang, D J, Fader, V K, Sondak   +4 more
openaire   +2 more sources